Daniel Blockmans

Dr. Daniel Blockmans, an internist from the University Hospital Gassisbury and an expert on giant cell arteritis, discusses groundbreaking findings on upadacitinib as a treatment alternative. He addresses the limitations of traditional glucocorticoid therapies and shares results from a Phase 3 trial showing upadacitinib's potential for sustained remission. The conversation also touches upon the safety profile, comparing it with tocilizumab and noting the importance of monitoring for opportunistic infections. Insights into differing treatment guidelines across regions add depth to the discourse.